Cargando…

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study

INTRODUCTION: The potential for ezogabine/retigabine (EZG/RTG) and its N-acetyl metabolite (NAMR) to inhibit the transporter protein P-glycoprotein-(P-gp)-mediated digoxin transport was tested in vitro. EZG/RTG did not inhibit P-gp. However, NAMR inhibited P-gp in a concentration-dependent manner. B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tompson, Debra J, Crean, Christopher S, Buraglio, Mauro, Arumugham, Thangam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206209/ https://www.ncbi.nlm.nih.gov/pubmed/25342921 http://dx.doi.org/10.2147/CPAA.S64131

Ejemplares similares

Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy
por: Ciliberto, Michael A, et al.
Publicado: (2012)

Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
por: Weisenberg, Judith LZ, et al.
Publicado: (2011)

Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey
por: Ishihara, Lianna, et al.
Publicado: (2015)

Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine
por: Brickel, Neil, et al.
Publicado: (2013)

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects
por: Trivedi, Ashit, et al.
Publicado: (2021)

No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug–Drug Interaction Study
por: Otani, Naoyuki, et al.
Publicado: (2019)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects
por: Yamazaki, Takao, et al.
Publicado: (2016)

Ezogabine skin discoloration is reversible after discontinuation
por: Mathias, Sally V., et al.
Publicado: (2017)

Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects
por: Wire, Mary Beth, et al.
Publicado: (2017)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects
por: Naderer, Odin, et al.
Publicado: (2018)

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin
por: Stopfer, P, et al.
Publicado: (2016)

Study of gender-related pharmacokinetics of ezogabine in Egyptian volunteers by a validated LC-MS/MS bioanalytical method
por: Elkady, Ehab F., et al.
Publicado: (2019)

Pharmacokinetic Considerations for Digoxin in Older People
por: Currie, Geoffrey M, et al.
Publicado: (2011)

Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects
por: Bækdal, Tine A., et al.
Publicado: (2019)

Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects
por: Chong, Edward, et al.
Publicado: (2014)

One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels
por: Yau, Michael C., et al.
Publicado: (2018)

Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial
por: Namdari, Rostam, et al.
Publicado: (2022)

Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein
por: Ledwitch, Kaitlyn V., et al.
Publicado: (2016)

Effect of green tea catechins on the pharmacokinetics of digoxin in humans
por: Kim, Tae-Eun, et al.
Publicado: (2018)

Efficacy of Retigabine on Acute Limbic Seizures in Adult Rats
por: Friedman, LK, et al.
Publicado: (2015)

European Survey of Prescriber Understanding of Risks Associated with Retigabine
por: Ishihara, Lianna, et al.
Publicado: (2015)

Survey of Physicians’ Understanding of Specific Risks Associated with Retigabine
por: Daniluk, Jerzy, et al.
Publicado: (2016)

Beneficial effect of retigabine on memory in rats receiving ethanol
por: Zwierzyńska, Ewa, et al.
Publicado: (2020)

KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients
por: Millichap, John J., et al.
Publicado: (2016)

Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
por: Komatsu, Toshiaki, et al.
Publicado: (2015)

Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: A comprehensive and critical review
por: Meirinho, Sara, et al.
Publicado: (2021)

Efficiency of individual dosage of digoxin with calculated concentration
por: Zhao, Li, et al.
Publicado: (2014)

Clinical utility of adjunctive retigabine in partial onset seizures in adults
por: Rejdak, Konrad, et al.
Publicado: (2012)

Efficacy of Retigabine in Adjunctive Treatment of Partial Onset Seizures in Adults
por: Splinter, Michele Y.
Publicado: (2013)

The effect of high dose digoxin on cytokines in healthy dogs.
por: Dülger, Haluk, et al.
Publicado: (2002)

Inappropriate use of digoxin in patients presenting with digoxin toxicity
por: Tatlisu, Mustafa Adem, et al.
Publicado: (2015)

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug
por: Salem, Farzaneh, et al.
Publicado: (2023)

Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine
por: Barrese, Vincenzo, et al.
Publicado: (2010)

The anticonvulsant retigabine is a subtype selective modulator of GABA (A) receptors
por: Treven, Marco, et al.
Publicado: (2015)

The anticonvulsant retigabine suppresses neuronal K(V)2-mediated currents
por: Stas, Jeroen I., et al.
Publicado: (2016)

Molecular Insights Into Binding and Activation of the Human KCNQ2 Channel by Retigabine
por: Garofalo, Barbara, et al.
Publicado: (2022)

Retigabine suppresses loss of force in mouse models of hypokalaemic periodic paralysis
por: Quiñonez, Marbella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aognemkpb63uf4m0f1f6apld5p